Investigation of primary hyperaldosteronism in the hypertensive patient: Why? When? How?;Recherche d'un hyperaldostéronisme primaire chez l'hypertendu: Pourquoi? Quand? Comment?

Archives des Maladies du Coeur et des Vaisseaux

Volumn 96, Issue 1, 2003, Pages 37-42

  Herpin, D ^a   Sosner, P ^a   Amar, J ^a   Chamontin, B ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUDROCORTISONE; RENIN; SPIRONOLACTONE;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADRENAL PHLEBOGRAPHY; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HUMAN; HYPERTENSION; HYPOKALEMIA; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; REVIEW; SALT LOADING; SCINTIGRAPHY; SCREENING TEST;

EID: 0037256810     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Sincloir AM, Isles CG, Brown I, Comeron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289-93.
2. Hiromatsu K, Yamada T, Yukimura Y et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-93.
3. Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC, How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? J Hypertens 1993; 11 (Suppl. 5): S 310-1.
4. Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240-3.
5. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary care population. Lancet 1999; 353: 40.
6. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-5.
7. Conn JW, Cohen EL, Rovner DR. Normokaliemic primary aldosteronism. JAMA 1965; 193: 200-6.
8. Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964; 190: 222-5.
9. Koplon NM. Commentary on incidence of primary aldosteronism: current estimations based on objective data. Arch Intern Med 1969; 123: 152-4.
10. Anderson GS, Toftdahl DB, Lund JO. The incidence rate of phoechromocytoma and Conn's syndrom in Denmark, 1977-1981. J Human Hypertens 1988; 2: 187-9.
11. Conn JW. The evolution of primary aldosteronism: 1954-1967. Harvey Lecture 1968; 62: 257-91.
12. Conn JW. An overall view of primary aldosteronism. In: Onesti G (ed). Hypertension: mechanisms and management. New York: Grune et Stratton, 1973: 471-80.
13. Massien-Simon C, Battaglio C, Chotellier G, Guyene TT, Duclos JM, Plouin PF. Conn's adenoma. Diagnostic and prognostic value of the measurement of potassium, renin, aldosterone levels and the aldosterone/renin ratio. Presse Med 1995; 24: 1238-42.
14. Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-34.
15. Plouin PF, Fiquet-Kempf B, Fakhoudi F, Rezolle JP, Guery B. Hypertension artérielle des hyperaldostéronismes primaires. Arch Mal Cœur 2000; 93: 1469-73.
16. Alderman MH, Budner N, Cohen H, Lamport B, Ooi WL. Prevalence of drug resistant hypertension. Hypertension 1988; 11: 1171-5.
17. Yakovlevitch M, Black HR. Resistant Hypertension in a tertiary care clinic. Arch Intern Med 1991; 151: 1786-92.
18. Bravo EL, Tarazi RC, Dustan HP et al. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74: 641-51.
19. Ragot S, Sosner P, Herpin D. HTA non contrôlées: intérêt pharmaco-économique d'un bilan hospitalier. Arch Mal Cœur 2002; 95: 733-7.
20. Gallay BJ, Ahmad S, Xu L, Toivolo B, Dovidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
21. Gregoire JR. Adjustment of the osmostat in primary aldosteronism. Mayo Clin Proc 1994; 69: 1108-10.
22. Herpin D, Chabrun A, Ragot S, Tran F. Exploration de l'oxe rénine-angiotensine-aldosterone chez l'hypertendu non contrôlé: Modalités, résultats et implications thérapeutiques. Arch Mol Cœur (Pratique) 2000; 92: 13-5.
23. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153: 2125-9.
24. Mc Kenna TJ, Sequeira SJ, Heffernon A, Chombers J, Cunninghom S. Diagnosis under random conditions of all disorders of the rennin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-7.
25. Chomontin B, Blanchouin-Emeric N, Amar J et al. Précurseurs de l'aldostérone et HTA avec hypokaliémie et nodule surrériolien non attribuée à un hyperaldostéronisme primaire. Arch Mal Cœur 1996; 89: 1055-8.
26. Kaplan NM, Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-4.
27. Lim PO, Young WF Jr, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353-61.
28. Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 1973; 37: 765-75.
29. Herpin D, Corvol P, Sudre Y, Demange J. Hyperaldostéronisme primoire por hyperplasie bilatérale des surrénales. Étude à propos d'un cas et revue de la littérature. Ann Med Interne 1978; 129: 557-64.
30. Gonguly A, Zoger PG, Luetscher JA. Primary aldosteronism due to unilateral adrenal hyperplasia. J Clin Endocrinol Metab 1980; 51: 1190-4.
31. Ganguly A, Grim CE, Weinberger MH. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism. N Engl J Med 1981; 305: 991-3.
32. Gordon RD, Gomez-Sanchez CE, Homlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma mosquerodes as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens 1987; 5 (suppl. 5): S 103-S 106.
33. Stowosser M. Hyperaldosteronism: primary versus tertiary. J Hypertens 2002; 20: 17-9.
34. Shapiro B, Grekin R, Gross MD, Freitas JE. Interference by spironoloctone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronism. Clin Nucl Med 1994; 19: 441-5.
35. Noscimbeni L, Lyonnet D, Vincent M et al. Cathétérisme des veines surrénales dons l'hepraldostéronisme primoire: aide à la décision chirurgicole? Arch Mol Cœur 2001; 94: 874-8.
36. Jeunemaître X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-5.